Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects
Information source: YM BioSciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: i.v. fentanyl and AeroLEF (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: YM BioSciences Official(s) and/or principal investigator(s): Diana Pilura, PhD, Study Director, Affiliation: YM BioSciences Paul Y Tam, MD, FACP, Principal Investigator, Affiliation: University of Toronto, Ontario, Canada
Summary
This was a pilot, phase I, two-period, fasting, bioavailability, safety,and pharmacokinetic
study evaluating single dose of i. v. fentanyl (200 µg) and single doses of 2 mL or 3 mL
inhaled AeroLEF (500 µg/mL) delivered by nebulization with the AeroEclipse BAN device
administered in normal healthy non-smoking subjects.
Clinical Details
Official title: A Pilot, Phase I, 2-Period, Fasting, Bioavailability, Safety and PK Study Evaluating A Single Dose Intravenous Fentanyl 200 µg) and Single Doses of 2 or 3 mL AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) in Normal Healthy Non Subjects
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Adverse Events
Secondary outcome: pharmacokinetics
Detailed description:
In Period I, subjects received an intravenous dose of fentanyl (200 µg) administered over 1
minute (Treatment A). Subjects then crossed over to Period II.
In Period II, subjects were randomly assigned to receive either 2 mL (1000 µg fentanyl;
Treatment B) or 3mL (1500 µg fentanyl; Treatment C) of AeroLEF delivered by nebulization
with the AeroEclipse BAN. Subjects were instructed to continue inhalation of AeroLEF for
approximately 1 minute beyond the point of nebulizer sputter to ensure that all aerosolized
medication was delivered. There was at least a 1 week washout period between study periods.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Non-smoking male or female with a minimum age of at least 18 years
- Body weight with aBMI range of 18. 5 - 27, with a minimum weight of at least 60 kg.
- Availability of subject for the entire study period and willingness to adhere to
protocol requirements, as evidenced by a signed, written, Informed Consent Form.
- Normal findings in the physical examination, vital signs (blood pressure between
100-140 - 60-90 mmHg, heart rate between 55-99 beats/min, respiration rate between
12-20 minute) and a 12 lead ECG.
- Negative for drug abuse, nicotine, alcohol, hepatitis B-surface antigen, hepatitis C
and HIV.
- If a female of child-bearing potential, the patient must have a negative urine
pregnancy test at screening and baseline.
- No clinical laboratory values outside of the Principal Investigator's acceptable
range, unless the Principal Investigator decided that the subject's values are not
clinically significant.
- Female subjects: (a) if pre-menopausal, have regular menstrual cycles (28-32 days),
and (b) are not pregnant prior to study start and avoids pregnancy during the study
and 1 month post drug administration, or (c) were surgically sterile for at least 6
months prior to enrollment, or (d) are post-menopausal for at least 1 year prior to
enrollment.
Exclusion Criteria:
- Known history of hypersensitivity to fentanyl.
- Presence or history of cardiac, pulmonary, gastrointestinal, endocrine,
neuromuscular, neurologic, hematological, liver or kidney disease, or any condition
known to interfere with absorption, distribution , metabolism, or excretion of drugs.
- History of drug abuse or narcotic dependency.
- Use of prescription medication within 30 days preceding entry int the study,
including any enzyme inducing/inhibitory drugs (excluding contraceptives).
- Participating in a clinical trial with an investigational drug within 30 days
preceding this trial.
- Blood donation within 45 days preceding this trial.
Locations and Contacts
University of Toronto, Toronto, Ontario M1L4S4, Canada
Additional Information
Starting date: October 2001
Last updated: July 1, 2008
|